Athira Pharma, Inc. (ATHA)
$
0.46
-0.01 (-2.17%)
Key metrics
Financial statements
Free cash flow per share
-2.2042
Market cap
17.9 Million
Price to sales ratio
0
Debt to equity
0.0299
Current ratio
7.2566
Income quality
1.0788
Average inventory
0
ROE
-1.4299
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company that focuses on developing small molecules aimed at restoring neuronal health and slowing neurodegradation. The company achieved a revenue of $0.00 indicating its niche market focus. Athira's lead product candidate, ATH-1017, is a blood-brain barrier-penetrating small molecule HGF/MET positive modulator currently undergoing LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for Alzheimer's disease treatment, as well as Phase 2 clinical trials for Parkinson's disease. In addition, the company has product candidates in the preclinical stage, including ATH-1019 for peripheral nervous system indications and ATH-1020 for neuropsychiatric conditions. The company incurred an interest expense of $0.00 reflecting its debt servicing obligations, while also recording an income tax expense of $0.00 indicating its tax obligations. Furthermore, Athira Pharma recorded an operating income of -$96,775,000.00 reflecting its earnings from core operations, and earned an interest income of $0.00 showcasing its financial investments. Established in 2011 and headquartered in Bothell, Washington, Athira Pharma was formerly known as M3 Biotechnology, Inc., a name it adopted in April 2019. Athira Pharma's stock is affordable at $0.40 making it suitable for budget-conscious investors. The stock enjoys a high average trading volume of 582,249.00 indicating strong liquidity in the market. With a market capitalization of $17,881,419.00 the company is classified as a small-cap player, which allows for potential growth within the sector. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Athira belongs to the Healthcare sector, driving innovation and growth through its development of promising therapeutic candidates.
Investing in Athira Pharma, Inc. (ATHA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bullish outlook. Always conduct your own research before investing.
Analysts predict Athira Pharma, Inc. stock to fluctuate between $0.22 (low) and $3.67 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-07-25, Athira Pharma, Inc.'s market cap is $17,881,419, based on 39,042,400 outstanding shares.
Compared to Meta Platforms, Inc. Class A Common Stock, Athira Pharma, Inc. has a Lower Market-Cap, indicating a difference in performance.
To buy Athira Pharma, Inc. (ATHA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ATHA. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Revenue: $0 | EPS: -$2.52 | Growth: -18.45%.
Visit https://www.athira.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $25.80 (2021-02-09) | All-time low: $0.22 (2025-04-08).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
accessnewswire.com
8 days ago
HIGHLIGHTS First three drill holes completed at RIB East Discovery successfully targeted stacked gravity, EM and structural anomalies (Figure 2), and intersected uranium mineralization, as part of the 2025 Angilak Exploration Program comprising 10,000 m of diamond drilling (Figure 1); Results represent the second new discovery of uranium mineralization - beyond the Lac 50 Deposit Trend - during the 2025 Angilak Exploration Program, within the Angikuni Basin along the 31 km RIB-Nine Iron Trend; Mineralization at RIB East Discovery is currently defined by three drill holes, all intersecting shallow uranium mineralization (10,000 CPS) over a continuous 1.0 m with max radioactivity of 30,730 CPS 1 (Figure 3a, b & 6) and a lower grade mineralized fracture intersected between 372 m and 372.6 m. RIBE-DD-003 was drilled 200 m along strike of RIBE-DD-002 and 150 m further into the hanging wall of an interpreted NW trending fault zone.
accessnewswire.com
15 days ago
WHITE ROCK, BC / ACCESS Newswire / July 14, 2025 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena Gold" or the "Company") is pleased to announce the successful completion of its comprehensive till survey at its Laird Lake gold project, located in Ontario's prolific Red Lake Gold District. The survey, completed ahead of schedule, marks a significant milestone in advancing the Company's exploration strategy on this highly prospective 4,158-hectare property, which spans over 10 km of the Balmer-Confederation Assemblage contact.
accessnewswire.com
a month ago
HIGHLIGHTS Completes first two drill holes of its 2025 Angilak Exploration Program comprising ~10,000m of diamond drilling. KU Discovery Target: The maiden drill hole, KU-DD-001 successfully targeted stacked gravity and structural anomalies (Figure 2), intersecting shallow high-grade uranium mineralization as well as numerous zones of lower-grade mineralization throughout the hole.
accessnewswire.com
2 months ago
HIGHLIGHTS The 2025 Angilak Exploration Program will comprise ~10,000 m of diamond drilling with two objectives: Lac 50 Deposit - expansion of the footprint of uranium mineralization. Stepping out along strike and at depth from the 2024 Exploration Target (as defined below), which remains open and unconstrained.
globenewswire.com
3 months ago
Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development
globenewswire.com
3 months ago
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25
accessnewswire.com
3 months ago
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VACAVILLE, CALIFORNIA / ACCESS Newswire / April 28, 2025 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena Gold" or the "Company") is pleased to announce the closing of a non-brokered private placement of flow-through common shares (the "FT Shares") previously announced on April 7, 2025, as amended April 21, 2025 (the "FT Offering"). The Company issued an aggregate of 15,300,000 FT Shares at a price of CDN $0.05 per FT Share for gross proceeds of CDN$765,000, which represents an oversubscription of CDN$265,000 of the originally planned financing.
accessnewswire.com
3 months ago
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / April 22, 2025 / ATHA Energy Corp. (TSXV:SASK)(FRA:X5U)(OTCQB:SASKF) ("ATHA" or the "Company") is pleased to announce that, further to its press releases dated March 31, 2025 and April 7, 2025, it has completed a fully-subscribed private placement offering of: (i) 16,766,490 flow-though common shares of the Company ("FT Shares") at a price of $0.47 per FT Share; and (ii) 3,475,000 FT Shares that may be immediately resold or donated to registered charities ("Charity FT Shares", and collectively with the FT Shares, the "Offered Shares") at a price of $0.61 per Charity FT Share for aggregate gross proceeds of approximately $10,000,000(the "Offering").
globenewswire.com
5 months ago
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS)
proactiveinvestors.com
6 months ago
ATHA Energy Corp (TSX-V:SASK, OTCQB:SASKF) revealed that a survey at its Angilak uranium project in Nunavut has expanded the known depth of uranium mineralization at the Lac 50 Deposit to over one kilometer. The survey also identified a new 25-kilometer conductive trend along the western margin of the Angikuni Basin, according to a statement from ATHA.
See all news